摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(叔丁氧羰基)氨基]烟酸 | 171178-34-0

中文名称
4-[(叔丁氧羰基)氨基]烟酸
中文别名
4-BOC-氨基烟酸
英文名称
4(tert-butoxycarbonylamino)pyridine-3-carboxylic acid
英文别名
4-((tert-Butoxycarbonyl)amino)nicotinic acid;4-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-3-carboxylic acid
4-[(叔丁氧羰基)氨基]烟酸化学式
CAS
171178-34-0
化学式
C11H14N2O4
mdl
MFCD03427724
分子量
238.243
InChiKey
FRZDXLXQZVISAQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    348.4±27.0 °C(Predicted)
  • 密度:
    1.293±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.363
  • 拓扑面积:
    88.5
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P280
  • 危险性描述:
    H317
  • 储存条件:
    室温下,保存于惰性气体中。

SDS

SDS:a59aba42d5b27c2623b7d912bb6c92f5
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Boc-aminonicotinic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Boc-aminonicotinic acid
CAS number: 171178-34-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14N2O4
Molecular weight: 238.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Bicyclic compounds capable of inhibiting tyrosine kinases of the
    申请人:Warner-Lambert Company
    公开号:US05654307A1
    公开(公告)日:1997-08-05
    Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.
    描述了新型4-取代氨基吡啶嘧啶和4-取代氨基吡啶嘧啶抑制剂表皮生长因子受体家族的酪氨酸激酶的作用,以及相应的药物组合物,这些药物在治疗癌症、关节炎中的滑膜侵袭、牛皮癣、血管再狭窄和血管生成方面非常有用,此外还可用于治疗胰腺炎和肾病,以及作为避孕药剂。
  • [EN] AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF<br/>[FR] COMPOSÉS AMIDES, COMPOSITIONS ET APPLICATIONS DE CEUX-CI
    申请人:ADVINUS THERAPEUTICS LTD
    公开号:WO2013042139A1
    公开(公告)日:2013-03-28
    The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. Formula (1). The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    本公开涉及替代酰胺化合物,这些化合物是脂肪酸酰胺解酶(FAAH)的抑制剂,包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防、管理或辅助治疗与脂肪酸酰胺解酶(FAAH)抑制相关的所有医疗状况中非常有用,例如疼痛,包括急性和术后疼痛,慢性疼痛,癌症疼痛,癌症化疗引起的疼痛,神经痛,伤害性疼痛,炎症性疼痛,背部疼痛,疾病引起的疼痛,如糖尿病性神经病变,神经病毒性疾病,包括人类免疫缺陷病毒(HIV),带状疱疹,如带状疱疹后神经痛;多发性神经病,神经毒性,机械神经损伤,腕管综合症,类似多发性硬化的免疫机制;睡眠障碍,焦虑和抑郁症,炎症性疾病,体重和进食障碍,帕森病,成瘾,痉挛,高血压或其他疾病。该公开还涉及酰胺化合物的制备过程。公式(1)。本公开还涉及制备这类化合物的方法,以及含有它们的药物组合物。
  • AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
    申请人:ADVINUS THERAPEUTICS LIMITED
    公开号:US20150065464A1
    公开(公告)日:2015-03-05
    The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    本公开涉及替代酰胺化合物,它们是脂肪酸酰胺解酶(FAAH)的抑制剂,包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用可接受盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防、管理或辅助治疗与脂肪酸酰胺解酶(FAAH)抑制相关的所有医疗状况中非常有用,如疼痛,包括急性和术后疼痛,慢性疼痛,癌症疼痛,癌症化疗引起的疼痛,神经痛,伤害性疼痛,炎症性疼痛,背部疼痛,疾病引起的疼痛,如糖尿病性神经病变,神经病毒性疾病,包括人类免疫缺陷病毒(HIV),带状疱疹,如带状疱疹后神经痛;多发性神经病,神经毒性,机械神经损伤,腕管综合症,免疫机制如多发性硬化症;睡眠障碍,焦虑和抑郁症,炎症性疾病,体重和进食障碍,帕森病,成瘾,痉挛,高血压或其他疾病。本公开还涉及酰胺化合物的制备过程。本公开还涉及制备这类化合物的方法,以及含有它们的药物组合物。
  • [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYME
    申请人:VIAMET PHARMACEUTICALS INC
    公开号:WO2014117090A1
    公开(公告)日:2014-07-31
    The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    这项即时发明描述了具有属酶调节活性的化合物,以及治疗由这些属酶介导的疾病、疾病或症状的方法。
  • [EN] COMPOSITIONS AND METHODS FOR MAKING HYBRID POLYPEPTIDES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE PRÉPARATION DE POLYPEPTIDES HYBRIDES
    申请人:UNIV YALE
    公开号:WO2020247605A1
    公开(公告)日:2020-12-10
    Compositions and methods of making hybrid polypeptides and other polymers are disclosed. For example, functionalized tRNA having a functional molecule including a benzoic acid or benzoic acid derivative acylated to the 3' nucleotide of a tRNA are provided. Functionalized tRNA having a functional molecule including a malonic acid or malonic acid derivative acylated to the 3' nucleotide of a tRNA are also provided. Methods of using the functionalized tRNA for making compounds including the functional molecule are also provided. The methods typically include providing or expressing a messenger RNA (mRNA) encoding the target polypeptide in a translation system including one or more functionalized tRNA wherein each functionalized tRNA recognizes at least one codon such that its functional molecule is incorporated into the polypeptide or other polymer during translation. The incorporation of the functional molecule can occur in vitro in a cell-free translation system, or in vivo in a host cell.
    本文揭示了制备混合多肽和其他聚合物的组成物和方法。例如,提供了具有功能分子(包括苯甲酸苯甲酸生物)酰化到tRNA的3'核苷酸的功能化tRNA。还提供了具有功能分子(包括丙二酸丙二酸生物)酰化到tRNA的3'核苷酸的功能化tRNA。还提供了使用功能化tRNA制备包括功能分子的化合物的方法。这些方法通常包括在翻译系统中提供或表达编码目标多肽的信使RNA(mRNA),该系统包括一个或多个功能化tRNA,其中每个功能化tRNA识别至少一个密码子,使其功能分子在翻译过程中被合并到多肽或其他聚合物中。功能分子的合并可以在细胞外翻译系统中体外进行,也可以在宿主细胞中体内进行。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-